Sanofi Inks 2 Oncology Agreements Totaling $1.2B

Seeking to boost its oncology presence, French drug giant Sanofi has inked separate agreements that together are worth about $1.2 billion.

In a deal worth roughly $435.4 million, Sanofi will license from Innate Pharma new technology to develop bispecific antibodies. Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the agreement.

Additionally, the Paris-based company will extend a 2012 agreement with Warp Drive Bio through which Sanofi will have access to Warp Drive’s small molecule assisted receptor targeting and genome mining platforms to discover new oncology therapeutics and antibiotics. Sanofi also will receive licenses to develop and commercialize candidates discovered during a five-year term, while Warp Drive could receive up to $750 million.